trending Market Intelligence /marketintelligence/en/news-insights/trending/IZIhqp8fBKqJNVKxJvHYlA2 content esgSubNav
In This List

Bluebird Bio prices $600M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bluebird Bio prices $600M common stock offering

Bluebird Bio Inc. priced its underwritten public offering of 3,243,244 shares at $185 per share, with plans to raise about $600 million.

The company granted the underwriters a 30-day option to purchase up to an additional 486,486 shares.

Bluebird Bio expects to raise approximately $600 million in gross proceeds from the offering, excluding any exercise of the underwriters' option to purchase additional shares.

The offering is expected to close on or about Dec. 15, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Bank of America Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers of the offering.